MedTrace Logo

Genetic Predictors of Lithium Response in Bipolar Disorder

NCT00252577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2020-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to identify genetic predictors of lithium response in bipolar disorder.

Conditions

Interventions

DRUG

Lithium treatment

Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • John R Kelsoe, MD · VA San Diego Healthcare System, San Diego, CA

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2016-03-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252577 on ClinicalTrials.gov